The effects of HIV on fertility by infection duration: evidence from African population cohorts before antiretroviral treatment availability. by Marston, Milly et al.
Marston, M; Nakiyingi-Miiro, J; Kusemererwa, S; Urassa, M; Michael,
D; Nyamukapa, C; Gregson, S; Zaba, B; Eaton, JW; ALPHA network,
(2017) The effects of HIV on fertility by infection duration: evidence
from African population cohorts before antiretroviral treatment avail-
ability. AIDS (London, England), 31 Suppl 1. S69-S76. ISSN 0269-
9370 DOI: https://doi.org/10.1097/QAD.0000000000001305
Downloaded from: http://researchonline.lshtm.ac.uk/4468816/
DOI: 10.1097/QAD.0000000000001305
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
The effects of HIV on fertility by infection duration:
evidence from African population cohorts before
antiretroviral treatment availability
Milly Marstona, Jessica Nakiyingi-Miiroc, Sylvia Kusemererwac,
Mark Urassab, Denna Michaelb, Constance Nyamukapad,
Simon Gregsond,e, Basia Zabaa, Jeffrey W. Eatone,
on behalf of the ALPHA network1
Objectives: To estimate the relationship between HIV natural history and fertility by
duration of infection in east and southern Africa before the availability of antiretroviral
therapy and assess potential biases in estimates of age-specific subfertility when using
retrospective birth histories in cross-sectional studies.
Design: Pooled analysis of prospective population-based HIV cohort studies in Masaka
(Uganda), Kisesa (Tanzania) and Manicaland (Zimbabwe).
Methods: Women aged 15–49 years who had ever tested for HIV were included.
Analyses were censored at antiretroviral treatment roll-out. Fertility rate ratios were
calculated to see the relationship of duration of HIV infection on fertility, adjusting for
background characteristics. Survivorship and misclassification biases on age-specific
subfertility estimates from cross-sectional surveys were estimated by reclassifying
person-time from the cohort data to simulate cross-sectional surveys and comparing
fertility rate ratios with true cohort results.
Results: HIV-negative and HIV-positive women contributed 15440 births and 86320
person-years; and 1236 births and 11240000 person-years, respectively, to the final
dataset. Adjusting for age, study site and calendar year, each additional year since HIV
seroconversion was associated with a 0.02 (95% confidence interval 0.01–0.03)
relative decrease in fertility for HIV-positive women. Survivorship and misclassification
biases in simulated retrospective birth histories resulted in modest underestimates of
subfertility by 2–5% for age groups 20–39 years.
Conclusion: Longer duration of infection is associated with greater relative fertility
reduction for HIV-positive women. This should be considered when creating esti-
mates for HIV prevalence among pregnant women and prevention of mother-to-child
transmission need over the course of the HIV epidemic and antiretroviral treatment
scale up. Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
The effects of HIV infection on fertility have been
extensively studied in generalized HIV epidemic settings
in sub-Saharan Africa [1–6]. This was of interest for two
reasons: first, to forecast the demographic impacts of
hyperendemic HIV [7,8] and, second, because HIV
prevalence among pregnant women was widely used for
estimating general population HIV prevalence levels and
trends [9–11]. More recently, the need to plan and
evaluate prevention of mother-to-child transmission
(PMTCT) programmes has further increased the
importance of accurate predictions of fertility of HIV-
positive women and changes therein.
Existing literature, largely based on analysis of cross-
sectional data, has demonstrated that the relationship
between HIV infection and fertility depends strongly on
age. Among young women (age 15–19 years) antenatal
care prevalence is higher than general population
prevalence because both pregnancy and HIV risk occur
among the subset of women who are sexually active, but
among older age groups the fertility rate ratio (FRR)
among HIV-positive women becomes increasingly lower
relative to HIV-negative women [1,12,13].
Currently, the Spectrum model (Avenir Health, Con-
necticut, USA) uses estimates of the FRR for HIV-
positive to HIV-negative women by age-group estimated
by Chen and Walker [1] to generate estimates of HIV
prevalence among pregnant women and need for
PMTCT. However, rather than a direct effect of age,
the lower prevalence among older pregnant women
may primarily be associated with reduced fertility during
later stages of HIV infection [5,14–17]. This distinction is
potentially important because of its interaction with the
stages of the HIVepidemic – during the early exponential
growth period of the epidemic, many more women
are recently infected, and so HIV-related subfertility will
be lower than later in the epidemic, even among older
women. Moreover, antiretroviral treatment (ART) is
disproportionately provided to those infected the longest
and experiencing the most serious clinical symptoms –
those who are expected to experience the greatest fertility
reductions. If the effects of HIV on fertility are strongly
related to the duration of infection, then these two effects
may contribute to biased predictions about need for
PMTCT services as ART programmes scale up.
Finally, the hypothesized relationship between duration
of HIV infection and fertility may influence our ability to
estimate the relationship between HIV and fertility.
Widely used estimates of age-specific FRRs by HIV
status rely on cross-sectional Demographic and Health
Survey data to compare fertility over the previous 3 years
among HIV-positive and HIV-negative women [1]. This
poses two potential biases (Fig. 1). First, it excludes
women who do not survive the 3-year period preceding
the survey. If duration of infection influences fertility,
then this survivorship bias would exclude women with
the lowest fertility, resulting in an underestimate of
subfertility based on cross-sectional surveys. Second,
retrospective analyses assume that the HIV status at the
time of the survey is unchanged over the previous 3 years.
For women who seroconverted during the 3 years prior
to the survey, this misclassifies some HIV-negative
person-time as HIV-positive, again potentially over-
estimating the true fertility of HIV-positive women.
In this analysis, we estimate the relationship between the
imputed duration of HIV infection and fertility using data
from three prospective general population open cohorts in
Uganda, Tanzania and Zimbabwe – all members of the
ALPHA network (London School of Hygiene & Tropical
Medicine, London, UK) [18]. The objective of this analysis
is to estimate the relationship of HIV natural history and
fertility in the absence of treatment, and as such we censor
the cohort data at the time when ART became available in
the population (population-wide fertility trends in these
cohorts since ART scale up have been described elsewhere
[19]). We use the prospective demographic and HIV
surveillance data to empirically quantify the expected
magnitude of survivorship and misclassification biases on
age-specific subfertility from cross-sectional surveys.
Methods
Sites and setting
Data come from three community-based demographic
and HIV open-cohort studies. Kisesa (managed by the
National Institute for Medical Research Mwanza) located
in northwestern Tanzania, was established in 1994 and has
a population of around 34 000. It is predominately rural
with a small trading centre on the main road. The average
HIV prevalence between 1994 and 2010 was 6% [20].
The Manicaland study (managed by the Biomedical
Research and Training Institute and Imperial College
London) in Zimbabwe was established in 1998. A
prospective household census (population size approxi-
mately 37 000) and general population cohort survey
(10 000–12 000) were initiated in 12 geographically
distinct study sites spread across three districts, with
follow-up rounds conducted every 2 or 3 years. The
Manicaland study sites comprise two small towns, four
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Fig. 1. Survivorship and misclassification bias.
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agricultural estates, two roadside settlements and four
subsistence farming areas. Overall adult HIV prevalence
was around 25% in the late 1990s and has declined steadily
to around 15% in 2012–2013 [21]. Masaka (managed by
MRC/UVRI Uganda Research Unit on AIDS) is
situated in rural southwest Uganda and was established
in 1989. Its initial population was around 10 000 which
then increased to 18 000 when 10 villages were added to
the census area in 2000. Average HIV prevalence between
1989 and 2011 was 8% [22].
Fertility data
In Kisesa, there are two sources of data that are used to
estimate fertility. At each demographic surveillance round
conducted one to two times per year, a proxy respondent
is asked whether each woman in the household gave birth
since the previous round and the birth outcome. Also, all
new members of the household, including newborns, are
linked to their mother if she lives in the household. These
two pieces of information are reconciled to give the date
of delivery of each birth observed in the demographic
surveillance site.
In Masaka, there are four sources of data for estimating
fertility. At each annual census, women of child-bearing
age are asked whether they were pregnant in the previous
12 months and the birth outcome. The names and
identification number of the child are recorded on the
mother’s record. Second, each new member of the
household is enumerated during the annual census and
the reasons for joining obtained. If the reason is new born,
the mother’s identification number is recorded on the
child’s census record. Third, village leaders are asked to
report all births in their village on a monthly basis to the
study clerks. This information is entered, and any child
reported by these recorders but not on census is added to
the census file. Fourth, every 3 years, all children aged less
than 18 years are asked about their parents to establish/
confirm who they are and their vital status.
In the Manicaland study, survey rounds are conducted
every 2–3 years. At each survey round, eligible women
are enumerated in a household census and invited to
participate in an open-cohort study. Participants report all
births since the previous survey round through a
structured questionnaire. For women who die between
survey rounds, any births occurring since the previous
survey round are recorded in a verbal autopsy interview
with the next of kin.
HIV data
In Kisesa, the HIV surveys were carried out separately to
the demographic surveillance rounds every 2–3 years,
and data were linked afterwards using unique personal
identifiers. In Masaka, HIV testing was done immediately
after demographic surveillance rounds that were used to
list those eligible for HIV testing. HIV testing took place
in the home for all sites apart from Kisesa where
temporary village clinics are used, to which people are
transported from their homes. Prior to the availability of
antiretroviral therapy, testing protocols used informed
consent without disclosure, so that participants did not
learn the results of the HIV research tests. In Manicaland,
following household census enumeration, research
assistants interview eligible individual participants to
collect dried blood spot samples, which are transported to
and analysed in an offsite laboratory.
Statistical analysis
Imputation of date of seroconversion
Calculating the fertility rate by duration of HIV infection
requires data about when a woman seroconverted, which
is not exactly observed. We generated 100 imputations for
the date of seroconversion for each HIV-positive woman.
For women who are observed HIV-negative in one
survey round and HIV-positive in a subsequent round
(seroconverters), we imputed dates of seroconversion
from a uniform distribution between the dates of the last
negative and first HIV-positive test.
For women who were already HIV positive the first time
they were tested in the cohort (prevalent cases), we
imputed 100 seroconversion dates from a distribution
determined by the convolution of the age-specific HIV
incidence rates and the probability of surviving from
seroconversion until the woman’s latest age at interview.
Fertility rate ratio by duration of infection
Person-time and live births of women of reproductive age
(15–49 years) who had ever tested for HIV in the studies
were eligible for inclusion in the analysis. HIV-negative
person-time for women with no subsequent positive test
was assumed to last for up to 5 years past their last negative
test, the exact cut-off point was determined by the HIV
incidence rates in the sites, defined as the time at which the
cumulated probability of becoming infected following the
last negative test reached 5%. Data for each cohort were
censored at the start of ART introduction (Kisesa March
2005, Masaka January 2004 and Manicaland June 2005) to
estimate the intrinsic relationship between HIVand fertility
before the availability of antiretroviral therapy. For women
ever testing HIV positive, imputed seroconversion dates
were used to assign person-time by HIV status.
The imputed duration of infection is defined as 0 for HIV-
negative and is treated as a continuous variable in years
following seroconversion. FRRs by HIV status and
duration of infection are calculated using piecewise
exponential regression allowing for clustering of births
in each women, adjusting for age-specific fertility in each
site and a log-linear trend in fertility over calendar time
centred on the year 2001. The analysis was repeated 100
times using independently imputed seroconversion dates.
The log of the hazard rate ratios from the imputations were
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combined using Rubin’s rules [23] to give confidence
intervals (CIs) that reflect the uncertainty about the exact
date of seroconversion. Older age at infection pre-ART is
associated with a shorter survival time [24] independent of
current age [25]. We investigated whether this could also
have an effect on subfertility classified by duration of
infection (model not shown).
The effects of survivorship and misclassification
bias in retrospective survey analysis
We quantified the potential magnitude of survivorship and
misclassification biases when estimating age-specific sub-
fertility from cross-sectional surveys by using the popu-
lation cohort data to simulate the 3-year retrospective
fertility history analysis and compared the resulting age-
specific FRRs with the true FRRs observed in the cohorts.
Person-time was classified in 3-year intervals 2000–2002
and 2003–2005 then aggregated over the 6-year period.
We calculated actual subfertility by age (adjusted for study
site, residence and calendar time), then calculated
subfertility by age as assumed in cross-sectional studies
by allocating all the person-time of women who were
positive at the end of the timeperiod toHIV positive for the
whole period (simulating misclassification) and removing
any person-time and births to women who died in the
period (simulating survivorship bias).
All analysis was done using Stata 14.1 (StataCorp. 2015.
Stata Statistical Software: Release 14. College Station,
TX: StataCorp LP).
Ethics statement
Each of the three sites contributing data to the pooled
analysis received ethical clearance from the appropriate
local ethics review bodies and from the corresponding
Institutional Review Boards at relevant collaborating
partner universities.
Results
Estimates of HIV subfertility by duration of
infection
The dataset compiled for women aged 15–49 years
contained 15 451 births and 86 280 person-years to
HIV-negative women, 993 births and 9580 person-years
to HIV-positive women and 315 births and 2510 person-
years with HIV status unknown. Prior to imputation, the
latter group comprised the time before a first positive test
and person-time in the seroconversion interval (Table 1).
Kisesa contributed the most births (54%) and person-
years (42%) (Table 1). Manicaland contributed the highest
number of births and person-years to HIV-positive
women (477 births, 5750 person-years) due to the higher
HIV prevalence in Zimbabwe. After imputation of
seroconversion dates, HIV-negative and HIV-positive
women contributed 15 440 births and 86 320 person–
years, and 1236 births and 11 240 person-years,
respectively. The total fertility rate over the pre-ART
time period used was highest in Kisesa at 6.2 followed by
Masaka at 5.2 and lowest in Manicaland at 3.1.
Crude fertility rates patterns were broadly similar in the
observed prevalent positive person-time compared with
the imputed positive person-time with the rates slightly
higher in the imputed positive person-time, consistent
with imputed positive being biased towards earlier duration
after seroconversion (not shown). Crude rates show a
decrease in fertility by duration of infection (Table 2).
Compared with HIV-negative women, the relative fertility
of HIV-positive 20–24-year-olds was 0.72 (95% CI 0.66–
0.79), and relative fertility further reduced with age (Table 3,
Model 1). The 15–19-year-old HIV-positive women have
higher fertility comparedwith thosewhoareuninfecteddue
to the fact that many women in this age group are not
sexually active and therefore are not exposed to HIV.
Including duration of infection in the model showed that
each additional year since seroconversion was associated
with a 0.979 (95% CI 0.965–0.995) times reduction in
fertility for HIV-positive women, adjusted for age, the
effect of age at seroconversion, study site and calendar year
(Model 2, Table 3). Accounting for duration attenuated the
relative fertility of positive women compared with negative
women to 0.78 (95% CI 0.70–0.88) and similarly for other
age groups (Model 2, Table 3).
Restricting the model to HIV-positivewomen (not shown)
shows that with increasing year of age at seroconversion,
there is an increase in the effect of duration on subfertility
(FFR 0.997, 95% CI 0.994–0.999).
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Table 1. Births and person-years by HIV status and study site for women aged 15–49 years who ever tested for HIV.
Kisesa Manicaland Masaka All sites
HIV status Births
Person-years
per 1000 Births
Person-years
per 1000 Births
Person-years
per 1000 Births
Person-years
per 1000
Negative 8581 38.11 2003 19.87 4867 28.30 15451 86.28
Positive 284 2.17 381 4.93 328 2.48 993 9.58
Unknown 162 1.12 96 0.85 57 0.54 315 2.51
Note for those HIV-negative women were included up to 5 years after last negative test.
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Estimates of survivorship bias in retrospective
surveys
Age-specific subfertility was larger in the ALPHA sites
compared with that found by Chen and Walker [1] apart
from the 15–19-year age group (Fig. 2a). The reduction in
fertility was 3–12% greater in the age groups 20–34 years
and somewhat larger at the oldest age groups, for example
41% lower in the 40–44-year age group. However, CIs
encompassed Chen and Walker estimates apart from the
40–44-year-old age group. Figure 2a compares the
observed subfertility by age in the cohorts (red dots) with
the subfertility estimates when analysed using the
assumptions of a retrospective cross-sectional survey (blue
triangles). Estimates with simulated misclassification and
survivorship bias attenuated the subfertility by age by
between 2 and 5% in the age groups between 20 and 39
years and 22% in the 40–44-year age group.
There was some evidence for variation of age-specific
subfertility by study site with subfertility in Manicaland
lower than in Masaka and Kisesa (Fig. 2b).
Discussion
These data show that longer duration of HIV infection is
associated with increased subfertility. Estimating age-
specific HIV subfertility using retrospective cross-sectional
surveys underestimates subfertility, particularly for older
ages, due to survivorship bias being more important at
longer duration of infection, which corresponds to greater
fertility-reducing effects of HIV infection.
Many studies have documented the effect of HIV on
fertility and on age-specific subfertility [1,4,12,13] at the
Fertility by duration of HIV infection Marston et al. S73
Table 2. Crude rates with imputed data by HIV status.
HIV negative Imputed positive All imputed data
Births
Person-years
per 1000
Fertility rate
per 1000 Births
Person-years
per 1000
Fertility rate
per 1000 Births
Person-years
per 1000
Fertility rate
per 1000
Age Group
15–19 2683 21.98 122.07 122 0.70 173.47 2806 22.69 123.66
20–24 4446 15.40 288.66 381 1.97 193.19 4826 17.37 277.83
25–29 3505 12.83 273.12 393 2.69 146.36 3898 15.52 251.18
30–34 2486 11.03 225.41 209 2.29 91.31 2694 13.31 202.35
35–39 1592 9.72 163.76 106 1.66 63.72 1698 11.39 149.14
40–44 621 8.53 72.87 21 1.25 16.53 642 9.78 65.66
45–49 107 6.83 15.66 4 0.67 6.11 111 7.50 14.80
HIV status
Negative 15440 86.32 178.87 15440 86.32 178.87
Positive 1236 11.24 109.98 1236 11.24 109.98
Duration of infection
1 year 130 0.81 160.13 130 0.81 160.13
1–2 years 265 1.87 142.15 265 1.87 142.15
3–4 years 252 1.87 135.13 252 1.87 135.13
5–6 years 205 1.68 121.66 205 1.68 121.66
7–8 years 145 1.39 104.62 145 1.39 104.62
9þ years 226 3.56 63.52 226 3.56 63.52
Study Site
Kisesa 8582 38.16 224.89 389 2.78 139.75 8971 40.94 219.10
Manicaland 2009 19.89 100.67 477 5.75 82.97 2480 25.65 96.70
Masaka 4855 28.26 171.78 370 2.70 136.78 5224 30.96 168.73
Calendar Year
1990 186 1.08 171.57 20 0.13 148.61 206 1.22 169.06
1991 336 1.61 209.15 34 0.19 179.94 370 1.80 206.05
1992 322 1.66 193.84 34 0.18 184.99 356 1.85 192.97
1993 232 1.68 138.42 36 0.18 197.64 268 1.86 144.22
1994 587 2.98 197.17 44 0.27 164.69 631 3.25 194.48
1995 1109 4.93 225.06 60 0.40 151.54 1170 5.33 219.56
1996 1080 5.02 214.92 61 0.41 149.27 1141 5.43 210.00
1997 1111 5.11 217.29 65 0.43 152.19 1176 5.54 212.30
1998 919 5.16 178.27 37 0.42 88.61 956 5.57 171.58
1999 1369 7.02 195.03 104 0.96 107.58 1473 7.98 184.49
2000 1562 9.17 170.37 155 1.48 104.97 1718 10.65 161.28
2001 1684 9.72 173.25 145 1.46 99.67 1829 11.18 163.65
2002 1711 10.23 167.27 169 1.49 113.05 1881 11.73 160.37
2003 1750 10.97 159.58 130 1.56 82.92 1880 12.53 150.02
2004 1242 7.92 156.90 108 1.26 86.04 1351 9.18 147.16
2005 237 2.06 115.13 34 0.42 81.86 271 2.48 109.51
Births and person-years are averaged over 100 datasets.
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population level during the pre-ART period. A number of
studies in sub-Saharan Africa have looked at disease
progression in relation to fertility, a case–control study in
Uganda found that high viral load was associated with
reduced rates of pregnancyand a reduction in live births [5],
despite being sexually active and not using contraception.
Also, a clinical cohort found that fertility is reduced from
the earliest stage of HIV infection with a large reduction in
fertility following the progression to AIDS [16] – this
finding was adjusted for sexual activity but not for
contraceptive use. A clinical cohort study in Tanzania also
found reduced fertility related to clinical stage of HIV [17]
adjusting for social and demographic characteristics. A
multisite HIV care and treatment programme analysis
showed a strong association between disease progression
and a reduction in the incidence of pregnancy [15].
Increased subfertility by duration of infection at the
population level could have both biological and beha-
vioural factors. Biologically, as well as increases in viral load
or decreases in CD4þ cell count as explanatory factors, the
semen quality of HIV-positive partners could be reduced
over the time of their infection [26–28] or their increased
illness could impact on their sexual activity. In terms of
behaviour, HIV-positive women are more likely to be
widowed [6,29,30] due to having had an HIV-positive
partner. Although voluntary testing and counselling was
rare in these sites prior to ART introduction, suspicion of
HIV status or illness in a partner with HIV may reduce the
desire for more pregnancies [31], which may be more
obvious at longer durations of infection and it may also
increase divorce or separation [6,30].
Increased age at seroconversion accelerated the effects of
infection duration on subfertility. Older age at infection
leads to shorter survival postinfection [24,25], so a shorter
duration to low CD4þ cell count and higher viral load
have been shown to reduce fertility. Also, at older ages of
seroconversion, it is more likely that the partner (who is
more likely to be older) has been infected for a longer
duration; therefore, there is a higher chance of
widowhood early on in the women’s HIV infection
lowering her changes of pregnancy. Finally, older women
are likely to have higher parity and therefore may have
lower desires for more children than a younger woman
who has none or few children.
Compared with the demographic and health survey (DHS)
analysis by Chen and Walker [1], ALPHA cohorts showed
greater fertility reductions among HIV-positive women
by 5-year age group, particularly in the older age groups.
Around half of this discrepancy was explained by biases
inherent in estimating subfertility from cross-sectional data
due to not including the person-years and births of those
who died prior to interview and classifying all person-years
according to the HIV status at time of interview.
S74 AIDS 2017, Vol 31 (Suppl 1)
Table 3. Effects of HIV on fertility by age and duration of infection.
Model 1 – no duration Model 2 – with duration
FRR 95% CI FRR 95% CI
Duration of infection 0.979 (0.964–0.995)
HIV status
HIV negative 1 1
HIV positive 0.72 (0.66–0.79) 0.78 (0.70–0.88)
Effects of HIV by age
15–19, HIV positive 2.02 (1.67–2.45) 1.95 (1.60–2.38)
20–24, HIV positive 1 1
25–29, HIV positive 0.86 (0.75–0.98) 0.90 (0.78–1.03)
30–34, HIV positive 0.69 (0.58–0.81) 0.74 (0.62–0.89)
35–39, HIV positive 0.73 (0.58–0.92) 0.81 (0.63–1.03)
40–44, HIV positive 0.46 (0.28–0.76) 0.52 (0.32–0.87)
45–49, HIV positive 0.90 (0.27–2.99) 1.01 (0.30–3.39)
Age group
15–19 0.50 (0.47–0.54) 0.50 (0.47–0.54)
20–24 1 1
25–29 0.96 (0.92–1.01) 0.96 (0.92–1.01)
30–34 0.81 (0.77–0.85) 0.81 (0.77–0.85)
35–39 0.63 (0.59–0.67) 0.63 (0.59–0.67)
40–44 0.31 (0.28–0.35) 0.31 (0.28–0.35)
45–49 0.09 (0.07–0.12) 0.09 (0.07–0.12)
Study site
Kisesa 1 1
Manicaland 0.66 (0.62–0.71) 0.67 (0.62–0.71)
Masaka 0.87 (0.82–0.92) 0.87 (0.82–0.92)
Calendar year 0.99 (0.99–1.00) 0.99 (0.99–1.00)
Results from exponential regression of fertility rates as a function of HIV status, age and duration of infection controlling for interaction between
study site and age (not shown), study site and calendar year (not shown). Calendar year is centred at 2001, age at seroconversion is centred at age
25. Pooled results based on 100 datasets for imputed date of seroconversion. CI, confidence interval; FRR, fertility rate ratio.
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Residual differences between our findings and those of
Chen and Walker [1] could have a number of causes. This
DHS analysis uses countries across south, east and western
Africa, whereas our analysis uses study sites from east and
southern Africa where Manicaland, Zimbabwe showed
lower subfertility than the two east Africa sites (although
CIs overlapped), which may indicate some differences in
subfertility and duration of infection in different settings as
found in previous studies [3,6]. Modern contraceptive use
by all women is much higher in Zimbabwe at 40.1% in
2005–2006 compared with Tanzania and Uganda, 22.5%
in 2004–2005 and 19.6% in 2006, respectively [32], which
may contribute to these differences [6]. Deliveries and the
deaths of children dying in early infancy (particularly in the
neonatal period) could be underreported in the ALPHA
studies due to recall bias or lackof knowledge on the part of
a proxy respondent, which would affect HIV-positive
women disproportionally due to the high infant mortality
of children infected through vertical transmission [33].
This could artificially increase subfertility estimates in the
cohort studies. The DHS will be prone to more recall bias
than the cohort studies; however, if analysis is limited to the
first few years prior to the interview and the respondent is
the women rather than a proxy, it is possible that this will
lead to less bias in reporting of births to infants who have
died in DHS compared with ALPHA studies. We find that
subfertility increases with duration of HIV infection in the
absence of ART. This has two important implications that
should be considered in future HIVepidemic estimates and
the estimates of need for PMTCT. First, over the course of
the epidemic, the distribution of duration of infection
changes. During the exponential growth phase, a higher
proportion of women will be recently infected, and as
incidence declines average duration of infection will
become longer. This means that the population-level
effects of HIV on fertility, and hence the relationship
between HIV prevalence measured among pregnant
women and general population prevalence, will change.
Second, initiation of antiretroviral treatment has been
disproportionately among women in later stages of
infection who might be expected to have the lowest
fertility rates. Thus, following ART scale up, not only
might women on ART have increased fertility [34], but
also the fertility of untreated HIV-positive women may be
higher because those who would have the lowest fertility
are selectively removed into the treatment group.
Implementation of Option Bþ over the past several
years, in which all pregnant women are initiated on
lifelong ART, will further change these dynamics. In light
of the demonstrated association between duration of
infection and fertility reduction, we recommend that
model-based approaches account for not only age but also
stage of infection and ART status when estimating HIV
prevalence among pregnant women and PMTCT need.
Our results also imply that there are differences in fertility
by setting. This underscores that, where possible, locally
available data such as prevalence from routine HIV testing
of pregnant women should be used in place of default
model values to inform appropriate model assumptions
about subfertility when generating estimates of
PMTCT need.
Finally, it is worth noting that survivorship bias will be less
important in the era of ART, as HIV mortality is lower.
The assumption that women who are HIV positive at the
time of interview have been infected for at least 3 years
will also become more realistic as longer durations of
infection become more common in the era of ART.
These factors should also be considered when interpret-
ing changes over time in the relationship between HIV
and fertility from cross-sectional surveys.
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